Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C43H67N15O12S2 |
| Molecular Weight | 1050.2193 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)[C@@H](C)CC
InChI
InChIKey=OXDZADMCOWPSOC-BQGUCLBMSA-N
InChI=1S/C43H67N15O12S2/c1-3-21(2)34-41(69)53-26(12-13-31(45)60)37(65)55-28(17-32(46)61)38(66)56-29(20-72-71-19-24(44)35(63)54-27(39(67)57-34)16-22-8-10-23(59)11-9-22)42(70)58-15-5-7-30(58)40(68)52-25(6-4-14-50-43(48)49)36(64)51-18-33(47)62/h8-11,21,24-30,34,59H,3-7,12-20,44H2,1-2H3,(H2,45,60)(H2,46,61)(H2,47,62)(H,51,64)(H,52,68)(H,53,69)(H,54,63)(H,55,65)(H,56,66)(H,57,67)(H4,48,49,50)/t21-,24-,25-,26-,27-,28-,29-,30-,34-/m0/s1
| Molecular Formula | C43H67N15O12S2 |
| Molecular Weight | 1050.2193 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16480986 | https://www.ncbi.nlm.nih.gov/pubmed/16288753 | https://www.ncbi.nlm.nih.gov/pubmed/23809437 | https://www.ncbi.nlm.nih.gov/pubmed/25102443
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16480986 | https://www.ncbi.nlm.nih.gov/pubmed/16288753 | https://www.ncbi.nlm.nih.gov/pubmed/23809437 | https://www.ncbi.nlm.nih.gov/pubmed/25102443
Arginine vasotocin (Argiprestocin, AVT) is the non-mammalian homologue of arginine vasopressin (AVP) and was first synthesized as an AVP analogue. It was later found in non-mammalian vertebrates and induces similar physiological effects as AVP. AVT is considered the primary antidiuretic hormone. AVT functions to regulate expression of social and reproductive behaviors.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Potential candidate genomic biomarkers of drug induced vascular injury in the rat. | 2011-12-01 |
|
| Protective effects of echinocystic acid isolated from Gleditsia sinensis Lam. against acute myocardial ischemia. | 2010-01 |
|
| Case report: profound hypotension associated with labetalol therapy in a patient with cerebral aneurysms and subarachnoid hemorrhage. | 2006-07 |
|
| Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients. | 2006-06 |
|
| Central oxytocinergic and dopaminergic mechanisms regulating penile erection in conscious rats. | 2005-08 |
|
| Vasotocin and vasopressin stimulation of the chloride secretion in the human bronchial epithelial cell line, 16HBE14o-. | 2005-04 |
|
| Vasopressin-stimulated CFTR Cl- currents are increased in the renal collecting duct cells of a mouse model of Liddle's syndrome. | 2005-01-01 |
|
| Non-muscle myosin II and myosin light chain kinase are downstream targets for vasopressin signaling in the renal collecting duct. | 2004-11-19 |
|
| Vasoplegic syndrome after off-pump coronary artery bypass surgery: an unusual complication. | 2004 |
|
| Acute renal failure secondary to milrinone in a patient with cardiac amyloidosis. | 2002-08 |
|
| Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. | 2000-02-15 |
|
| Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension. | 2000-01 |
|
| Pulmonary vasodilatory response to neurohypophyseal peptides in the rat. | 1992-08 |
|
| Effect of hypotension and hyperosmolality on vasopressin and ACTH responses to hypoglycemia in conscious dogs. | 1992-08 |
|
| Evidence that apomorphine induces penile erection and yawning by releasing oxytocin in the central nervous system. | 1989-05-30 |
|
| Penile erection and yawning induced by oxytocin and related peptides: structure-activity relationship. | 1989-05-01 |
|
| [Effect of lysyl vasopressin and vasotocin on a disorder of the conditioned avoidance reaction by a serotonin receptor blockader]. | 1983-02 |
|
| [Prevention of testosterone-vasopressin induced necrosis of the kidney cortex by cyproterone acetate]. | 1979-07 |
|
| Cyproterone acetate-promoted prevention of renal cortical necrosis following testosterone and vasopressin administration. | 1979-02 |
|
| An approach to the control of massive hemorrhage in cyclophosphamide-induced cystitis by intravenous vasopressin: a case report. | 1978-08 |
|
| Effect of vasopressin administration on renal haemodynamic changes in rats treated with ACTH. | 1973-10-22 |
|
| Responses of the rat foetus to maternal injections of adrenaline and vasopressin. | 1971-10 |
|
| Ventricular extrasystoles induced by epinephrine, nicotine, ethanol, and vasopressin in dogs with myocardial lesions. | 1969-07 |
Sample Use Guides
fish: 10 ug/g caused a progressive increase of electric organ discharges rate.
green anole lizard: 15 ug regulates reptile social behavior
Route of Administration:
Intraperitoneal
In vitro stimulation of the aquatic Xenopus urinary bladder with 10 nM Argiprestocin (arginine vasotocin) had no clear effect on the subcellular distribution of urinary bladder-type aquaporin, AQP-x2. When the Argiprestocin concentration was increased to 1 uM, however, AQP-x2 was partially transferred to the apical plasma membrane.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:19:42 GMT 2025
by
admin
on
Mon Mar 31 18:19:42 GMT 2025
|
| Record UNII |
W6S6URY8OF
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C548
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m11399
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
PRIMARY | Merck Index | ||
|
10034060
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
PRIMARY | |||
|
100000086599
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
PRIMARY | |||
|
1483
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
PRIMARY | |||
|
W6S6URY8OF
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
PRIMARY | |||
|
Vasotocin
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
PRIMARY | |||
|
78364
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
PRIMARY | |||
|
C87380
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
PRIMARY | |||
|
CHEMBL2370156
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
PRIMARY | |||
|
SUB05562MIG
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
PRIMARY | |||
|
113-80-4
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
PRIMARY | |||
|
DTXSID40873492
Created by
admin on Mon Mar 31 18:19:42 GMT 2025 , Edited by admin on Mon Mar 31 18:19:42 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
